Literature DB >> 19205501

Resolution of macular edema in idiopathic juxtafoveal telangiectasis using PDT.

Maria G Kotoula1, Dimitrios Z Chatzoulis, Constantinos H Karabatsas, Aristoteles Tsiloulis, Evangelia E Tsironi.   

Abstract

A 57-year-old woman was treated by photodynamic therapy for macular edema due to idiopathic juxtafoveal telangiectasis (presumed type 1A) without subretinal neovascularization. Initial visual acuity of the treated eye was 20/200 and it improved to 20/40 by 3 months after the photodynamic therapy session. Visual acuity remained stable 32 months after the treatment. Color photographs and fundus fluorescein angiography before and after photodynamic therapy revealed regression of hemorrhages, exudates, and fluorescein leakage. Photodynamic therapy has long-term benefits for the patient with idiopathic juxtafoveal telangiectasis, presumed type 1A, because it can improve visual acuity and macular edema.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19205501     DOI: 10.3928/15428877-20090101-10

Source DB:  PubMed          Journal:  Ophthalmic Surg Lasers Imaging        ISSN: 1542-8877


  4 in total

1.  Use of intravitreal bevacizumab injections to treat type 1 idiopathic macular telangiectasia.

Authors:  Byung Gil Moon; Yoon Jeon Kim; Young Hee Yoon; Joo Yong Lee
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-08-24       Impact factor: 3.117

2.  Intravitreal triamcinolone for management of idiopathic juxtafoveolar telangiectasis.

Authors:  Nitin Nema; Michael S Ip
Journal:  Oman J Ophthalmol       Date:  2010-01

3.  Clinical features of idiopathic juxtafoveal telangiectasis in Koreans.

Authors:  Seung Woo Lee; Sung Min Kim; Yun Taek Kim; Se Woong Kang
Journal:  Korean J Ophthalmol       Date:  2011-07-22

4.  Macular oedema in idiopathic macular telangiectasia type 1 responsive to aflibercept but not bevacizumab.

Authors:  O'Sam Shibeeb; Anagha Vaze; Mark Gillies; Timothy Gray
Journal:  Case Rep Ophthalmol Med       Date:  2014-10-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.